Use of Pregabalin in Patients with Painful Neuropathic Disorders under the Care of General Practitioners in the U.K.
- 15 January 2009
- journal article
- research article
- Published by Wiley in Pain Practice
- Vol. 9 (1) , 18-34
Abstract
Purpose: To examine the use of pregabalin in patients with painful neuropathic disorders under the care of general practitioners (GPs) in the U.K. Materials and Methods: Using a large U.K. database of GP encounters, we identified all persons aged ≥ 18 years with at least one GP encounter with a diagnosis of a painful neuropathic disorder (eg, postherpetic neuralgia, diabetic peripheral neuropathy) between January 1, 2004 and July 31, 2006. Among these patients, we then identified those who initiated therapy with pregabalin; the date of initial receipt of pregabalin was designated the “index date.” We then examined use of pregabalin over the 6‐month period following this date (“follow‐up”), as well as changes in the use of other pain‐related medications (eg, opioids, tricyclic antidepressants [TCAs], other antiepileptics [AEDs]) between the 6‐month period preceding the index date (“pretreatment”) and follow‐up. Patients with less than 6 months of pretreatment and follow‐up data were excluded, as were those without any encounters during pretreatment for a painful neuropathic disorder. Results: A total of 1,400 patients (1.4% of all identified patients with painful neuropathic disorders) initiated therapy with pregabalin and met all other entry criteria; mean age was 62 years, and 58% were women. During pretreatment, most (54%) patients received three or more different types of pain‐related medications. During follow‐up, patients averaged four prescriptions for pregabalin, totaling 93 therapy days. Compared with pretreatment, fewer patients received other pain‐related medications during follow‐up, including TCAs (37% during pretreatment vs. 27% during follow‐up), opioids (64% vs. 55%), and AEDs other than pregabalin (36% vs. 16%) (all P < 0.01). Conclusions: In the U.K., many patients prescribed pregabalin by their GPs may have been refractory to other pain‐related medications. Use of these medications declined following initiation of pregabalin therapy.Keywords
This publication has 20 references indexed in Scilit:
- Pharmacological Management of Chronic Neuropathic Pain – Consensus Statement and Guidelines from the Canadian Pain SocietyPain Research and Management, 2007
- Pregabalin in central neuropathic pain associated with spinal cord injuryNeurology, 2006
- Pregabalin for peripheral neuropathic pain: results of a multicenter, non-comparative, open-label study in Indian patients2006
- Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13‐week, randomized trialCurrent Medical Research and Opinion, 2005
- Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimensPain, 2005
- Relief of painful diabetic peripheral neuropathy with pregabalin: A randomized, placebo-controlled trialThe Journal of Pain, 2005
- Pregabalin relieves symptoms of painful diabetic neuropathyNeurology, 2004
- Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trialPain, 2004
- Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trialPain, 2004
- Pregabalin for the treatment of postherpetic neuralgiaNeurology, 2003